Market Update (NASDAQ:AMGN): Amgen Submits Applications In The US And Europe For Kyprolis® (carfilzomib) For The Treatment Of Relapsed Multiple Myeloma

[PR Newswire] – THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Jan. 27, 2015 /PRNewswire/ — Amgen (AMGN) and its subsidiary Onyx Pharmaceuticals, Inc., today announced the submission of a supplemental New Drug . . . → Read More: Market Update (NASDAQ:AMGN): Amgen Submits Applications In The US And Europe For Kyprolis® (carfilzomib) For The Treatment Of Relapsed Multiple Myeloma Similar Articles: Stock Update (NASDAQ:AMGN): The Amgen Foundation Expands Amgen Scholars Program to 17 Top Educational Institutions Worldwide Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen ovarian cancer drug fails to improve overall survival Company Update: Amgen Inc (NASDAQ:AMGN) – Amgen submits U.S. application to sell cholesterol-fighting drug